was extremely well done and worth the price of admission alone,” says Del Brady about RedPath's participation in Early Stage East's Bio-Life-Tech conference in 2005. ESE provides a coaching session with industry experts to help the companies create informative and dynamic eight minute presentations for our Bio-Life-Tech conference. At the conference the companies present in front of an audience of venture capitalists who are specifically interested in investing in the life sciences arena. “Challenging, effective, and fun, it clearly made a difference in the way I presented and communicated the value of RedPath ” Del Brady added.
Last month Redpath announced its partnership with CBLPath as the exclusive provider of RedPath's PathFinderTG ™ on the private pathology market. The Pathfinder TG™ resolves equivocal diagnoses for clinicians and pathologists when standard tests are inconclusive. It helps patients by reducing the likelihood of incomplete or unnecessary treatment. In addition, The PathFinderTG ™ has been clinically validated in a range of specialty areas such as cancer of the gastrointestinal tract, the pancreas and the brain.
“This partnership reflects a natural yet strategic progression from the top academic cancer centers and large regional hospitals that comprise our current customer base to the private outpatient market,” said Del Brady. CBLPath is a landmark anatomic pathology laboratory that delivers advanced diagnostic testing and innovative technology solutions to its physician-clients across the nation. “We believe CBLPath is the best channel partner we could have to assist us in our growth and transition” she stated.
For more information about RedPath Integrated Pathology, please visit their website at www.redpathip.com .